Mercy to Participate in Large-Scale Cancer Screening Study
Event summary
- Mercy is participating in the REACH study, a three-year clinical trial evaluating GRAIL's Galleri® multi-cancer early detection (MCED) test.
- The study will enroll up to 50,000 Medicare beneficiaries, comparing those receiving the Galleri test with standard care.
- Mercy was previously involved in earlier clinical studies of the Galleri test.
- The study aims to assess the clinical impact of the Galleri test on a population at high risk for cancer, Medicare beneficiaries aged 50+.
The big picture
The study highlights the growing interest in multi-cancer early detection as a potential tool to improve outcomes for an aging population. Given that Medicare beneficiaries represent a significant portion of cancer diagnoses and mortality, the results of the REACH study could have a substantial impact on healthcare spending and patient care pathways. GRAIL's Galleri test represents a significant investment in preventative oncology, and its success hinges on demonstrating real-world clinical benefit.
What we're watching
- Clinical Validation
- The REACH study's results will be critical in determining the clinical utility and cost-effectiveness of multi-cancer early detection tests, potentially influencing Medicare coverage decisions.
- Adoption Rate
- The pace at which the Galleri test is adopted by other healthcare systems, beyond Mercy’s initial involvement, will indicate the level of confidence in its efficacy and the willingness of patients and providers to embrace it.
- Regulatory Landscape
- How the FDA and CMS ultimately classify and regulate MCED tests will significantly impact their accessibility and reimbursement, shaping the long-term market viability of GRAIL’s Galleri and similar products.
Related topics